Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gamida Cell Ltd (GMDA)
NASDAQ:GMDA
Holding GMDA?
Track your performance easily
GMDA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.03 - $2.51
Previous Close$0.03
Volume23.04M
Average Volume (3M)9.60M
Market Cap
$5.04M
Enterprise Value$30.53M
Total Cash (Recent Filing)$60.43M
Total Debt (Recent Filing)$85.93M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
May 07, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding154,050,953
10 Day Avg. Volume44,006,456
30 Day Avg. Volume9,604,126
Standard Deviation0.29
R-Squared0.03
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.11
Enterprise Value/Gross Profit-23.78
Enterprise Value/Ebitda-0.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Gamida Cell News
Ownership Overview
6.14% Insiders
4.57% Mutual Funds
10.97% Other Institutional Investors
78.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GMDA FAQ
What was Gamida Cell Ltd’s price range in the past 12 months?
Gamida Cell Ltd lowest stock price was $0.03 and its highest was $2.51 in the past 12 months.
What is Gamida Cell Ltd’s market cap?
Currently, no data Available
When is Gamida Cell Ltd’s upcoming earnings report date?
Gamida Cell Ltd’s upcoming earnings report date is May 07, 2024 which is 229 days ago.
How were Gamida Cell Ltd’s earnings last quarter?
Gamida Cell Ltd released its earnings results on Mar 27, 2024. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.152 by $0.172.
Is Gamida Cell Ltd overvalued?
According to Wall Street analysts Gamida Cell Ltd’s price is currently Overvalued.
Does Gamida Cell Ltd pay dividends?
Gamida Cell Ltd does not currently pay dividends.
What is Gamida Cell Ltd’s EPS estimate?
Gamida Cell Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gamida Cell Ltd have?
Gamida Cell Ltd has 154,050,950 shares outstanding.
What happened to Gamida Cell Ltd’s price movement after its last earnings report?
Gamida Cell Ltd reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.152. Following the earnings report the stock price went down -82.353%.
Which hedge fund is a major shareholder of Gamida Cell Ltd?
Among the largest hedge funds holding Gamida Cell Ltd’s share is ARK Investment Management LLC. It holds Gamida Cell Ltd’s shares valued at 884K.
---
Gamida Cell Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
GMDA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 724.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.10%
Trailing 12-Months
Company Description
Gamida Cell Ltd
Gamida Cell Ltd. is a clinical stage biopharmaceutical company engaging in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
---
GMDA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Gritstone Oncology
―
Corbus Pharmaceuticals
―
Karyopharm Therapeutics
―
Madrigal Pharmaceuticals
―
Best Analysts Covering GMDA
1 Year
1 Year Success Rate
4/22 ratings generated profit
1 Year Average Return
-37.23%
reiterated a buy rating 2 years ago
Copying Mark Breidenbach's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -37.23% per trade.
---